Skip to main content
Explore URMC
URMC / Research / Clinical Trials / Study Details

Amyloidosis: A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Research Question:
Is daratumumab when given with three other drugs [cyclophosphamide, bortezomib (VELCADE®) and dexamethasone] useful for treating patients with Amyloid light chain Amyloidosis (also known as AL Amyloidosis)?

Basic Study Information

There are two treatment groups in this study. The study medication will be given in treatment cycles, and each cycle is 28 days long. Group A: Cyclophosphamide, bortezomib (VELCADE®) and dexamethasone (CyBorD). Group B: Daratumumab plus cyclophosphamide, bortezomib (VELCADE®) and dexamethasone (CyBorD)

Location: Cancer Center
Study Web URL:
Study Reference #: IMMY17131

Lead Researcher (Principal Investigator)

Lead Researcher:  Frank Passero

Study Contact Information

Study Coordinator: Andrew Bui
Phone: (585) 276-4405

Additional Study Details

Learn More About These Conditions

More information about Amyloidosis

Return to Search